Pneumococcal conjugate vaccine

Pneumococcal conjugate vaccine
Name	Pneumococcal conjugate vaccine
Type	conjugate
Target	Streptococcus pneumoniae
Vaccine type	Conjugate vaccine
Routes	Intramuscular
Schedule	Varies by national guidelines

Pneumococcal conjugate vaccine

Pneumococcal conjugate vaccine prevents disease caused by Streptococcus pneumoniae and is used to reduce invasive pneumococcal disease such as pneumonia, meningitis and sepsis. It has been implemented in immunisation programmes by health authorities such as the World Health Organization, the Centers for Disease Control and Prevention, and national agencies including Public Health England and the European Medicines Agency. Development and deployment have involved collaborations among pharmaceutical companies like Wyeth, Pfizer, and GlaxoSmithKline as well as funding from organizations such as the Gavi, the Bill & Melinda Gates Foundation, and the WHO.

Medical uses

Pneumococcal conjugate vaccine is indicated for use in infants, children, and selected adult populations to prevent invasive disease and reduce nasopharyngeal carriage of Streptococcus pneumoniae. National programmes in countries such as United States, United Kingdom, Australia, Japan, and South Africa recommend routine childhood immunisation to lower the burden of pneumonia, otitis media, and bacteraemia. High-risk adult groups recommended by advisory committees like the Advisory Committee on Immunization Practices and the European Centre for Disease Prevention and Control include people with asplenia, chronic cardiac conditions, chronic pulmonary disease, and immunocompromising conditions managed by institutions such as Mayo Clinic and Johns Hopkins Hospital. Use during outbreaks has been supported by agencies like the Centers for Disease Control and Prevention and humanitarian organisations including Doctors Without Borders.

Composition and serotypes

Formulations contain capsular polysaccharides from multiple pneumococcal serotypes conjugated to carrier proteins such as diphtheria toxoid variants used in vaccines licensed by manufacturers like Pfizer and GlaxoSmithKline. Licensed preparations have included 7-valent, 10-valent, 13-valent, and higher-valent formulations developed by companies including Wyeth and GSK to target serotypes prevalent in surveillance data collected by networks like the Global Influenza Surveillance and Response System and national reference labs such as the CDC Streptococcus Laboratory. Serotype selection has been informed by epidemiological studies in regions such as Sub-Saharan Africa, Southeast Asia, Latin America, and Europe and by genomic surveillance efforts from institutions like the Wellcome Sanger Institute and the Institut Pasteur.

Immunogenicity and mechanism of action

Conjugation of capsular polysaccharides to protein carriers converts T-cell–independent antigens into T-cell–dependent antigens, enhancing immunogenicity in infants, neonates, and immunosenescent elderly populations monitored in cohorts from centres such as Imperial College London and Harvard Medical School. Vaccine-induced B-cell responses generate serotype-specific opsonophagocytic antibodies that promote clearance of Streptococcus pneumoniae by phagocytes, a mechanism studied in laboratories at National Institutes of Health, Karolinska Institutet, and Institut Pasteur. Immunological bridging studies and clinical immunogenicity trials conducted by regulatory bodies including the Food and Drug Administration and the European Medicines Agency assess surrogate markers such as opsonophagocytic activity and serotype-specific IgG titres.

Efficacy and safety

Randomised controlled trials and post-licensure surveillance led by organisations like the Cochrane Collaboration, the World Health Organization, and national public health agencies demonstrated reductions in invasive pneumococcal disease, hospitalisation for pneumonia, and all-cause mortality in infants in settings ranging from Gambia to United States. Vaccine effectiveness varies with serotype prevalence, herd immunity effects documented after introduction in countries such as United Kingdom and Australia, and serotype replacement observed in surveillance from Netherlands and Canada. Safety profiles established by regulatory authorities including the Food and Drug Administration and the European Medicines Agency report local injection-site reactions and transient systemic events; rare serious adverse events are monitored through pharmacovigilance systems like VAERS and the European Pharmacovigilance Risk Assessment Committee.

Vaccination schedules and recommendations

Schedules differ by country and age group, with infant schedules commonly at 2, 4, 6 and 12–15 months in programmes of United States, United Kingdom, Germany, and Japan and catch-up or single-dose strategies for older children and adults recommended by the Advisory Committee on Immunization Practices and national immunisation technical advisory groups such as those in India and Brazil. Co-administration with routine childhood vaccines from manufacturers like Sanofi and GSK has been evaluated in clinical trials overseen by institutions including Oxford Vaccine Group and Children's Hospital of Philadelphia. Policy decisions consider cost-effectiveness analyses performed by economic modelling groups at organisations like the World Bank and the Institute for Health Metrics and Evaluation.

History and development

Early polysaccharide vaccines were developed in the mid-20th century with contributions from researchers at institutions such as Rockefeller University and Johns Hopkins University, but limited immunogenicity in infants motivated conjugate approaches pioneered by investigators at University of Rochester and companies like Wyeth. Key milestones include licensure of the 7-valent formulation, subsequent development of 10-valent and 13-valent vaccines by GlaxoSmithKline and Pfizer, and global introduction campaigns supported by Gavi and the Bill & Melinda Gates Foundation. Regulatory approvals and large-scale trials involved collaborations with bodies including the Food and Drug Administration, the European Medicines Agency, and national ministries of health in countries such as Kenya, South Africa, and Mexico.

Category:Vaccines